Monday - December 29, 2025
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
December 26, 2025
NEW BRUNSWICK, New Jersey, Dec. 26 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study

*

The Phase 2b DUPLEX-AD proof-of-concept study (95475939ADM2001) evaluated JNJ-95475939 (JNJ-5939) for the treatment of moderate to severe atopic dermatitis (AD). The results of a planned interim analysis met prespecified criteria for early terminat . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products